[Clinical development and future perspective of biological agents].
Biological agents targeting against a series of pro-inflammatory cytokines have provided an enormous impact on the therapeutic management on inflammatory disorders such as rheumatoid arthritis. Clinical development of biological agents in Japan, particularly, TNF inhibitors, has been reviewed in this paper, and future perspective is discussed.
Takeuchi
Tsutomu
T
Division of Rheumatology, Department of Internal Medicine, Saitama Medical Center, Saitama Medical University.
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D018501:Antirheumatic Agents; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000209:etiology; D016207:Cytokines / Q000276:immunology / Q000502:physiology; D015195:Drug Design; D006801:Humans; D018836:Inflammation Mediators / Q000276:immunology / Q000502:physiology; D000069285:Infliximab; D007375:Interleukin-1; D015850:Interleukin-6; D007564:Japan; D047889:Receptors, Tumor Necrosis Factor, Type II; D014409:Tumor Necrosis Factor-alpha
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D016207:Cytokines; D018836:Inflammation Mediators; D007375:Interleukin-1; D015850:Interleukin-6; D047889:Receptors, Tumor Necrosis Factor, Type II; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab